SonoMotion secures a $1.75M non-dilutive SBIR grant funding from the NIH for the development of Stone Clear™.


SonoMotion reaches agreement with the University of Washington for exclusive license to an extensive IP portfolio related to Break Wave™ and Stone Clear™.


 Positive First-In-Man Stone Clear™ clinical trial results presented at the American Urological Association (AUA) meeting in New Orleans.


SonoMotion brings onboard Dr. Oren Levy as its Chief Executive Officer and Chairman of the Board.